Sohaib Mir, Investment Director at LifeArc Ventures, congratulates portfolio company, AviadoBio, on its exclusive option and license agreement with Astellas Pharma
Sohaib Mir, Investment Director at LifeArc, said:
“Congratulations to our portfolio company AviadoBio on announcing an exclusive option and license agreement with Astellas Pharma for its innovative gene therapy candidate AVB-101, which is currently in Phase 1/2 development for patients with frontotemporal dementia with progranulin mutations (FTD-GRN). LifeArc Ventures is proud to have supported AviadoBio in its seed and Series A funding rounds, and the agreement with Astellas will help to accelerate the route to market for AVB-101, bringing hope to patients with this devastating form of early onset dementia and other challenging neurological conditions.”
